Your browser doesn't support javascript.
loading
Immunogenicity, safety, and tolerability of a recombinant measles-vectored Lassa fever vaccine: a randomised, placebo-controlled, first-in-human trial.
Tschismarov, Roland; Van Damme, Pierre; Germain, Clara; De Coster, Ilse; Mateo, Mathieu; Reynard, Stephanie; Journeaux, Alexandra; Tomberger, Yvonne; Withanage, Kanchanamala; Haslwanter, Denise; Terler, Katherine; Schrauf, Sabrina; Müllner, Matthias; Tauber, Erich; Ramsauer, Katrin; Baize, Sylvain.
Afiliación
  • Tschismarov R; Themis Bioscience, Vienna, Austria, a subsidiary of Merck & Co, Rahway, NJ, USA. Electronic address: roland.tschismarov@themisbio.com.
  • Van Damme P; Center for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, Antwerp, Belgium.
  • Germain C; Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Lyon, France; Centre International de Recherche en Infectiologie, Université de Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, Lyon, France.
  • De Coster I; Center for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, Antwerp, Belgium.
  • Mateo M; Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Lyon, France; Centre International de Recherche en Infectiologie, Université de Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, Lyon, France.
  • Reynard S; Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Lyon, France; Centre International de Recherche en Infectiologie, Université de Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, Lyon, France.
  • Journeaux A; Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Lyon, France.
  • Tomberger Y; Themis Bioscience, Vienna, Austria, a subsidiary of Merck & Co, Rahway, NJ, USA.
  • Withanage K; Center for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, Antwerp, Belgium.
  • Haslwanter D; Themis Bioscience, Vienna, Austria, a subsidiary of Merck & Co, Rahway, NJ, USA.
  • Terler K; Themis Bioscience, Vienna, Austria, a subsidiary of Merck & Co, Rahway, NJ, USA.
  • Schrauf S; Themis Bioscience, Vienna, Austria, a subsidiary of Merck & Co, Rahway, NJ, USA.
  • Müllner M; Themis Bioscience, Vienna, Austria, a subsidiary of Merck & Co, Rahway, NJ, USA.
  • Tauber E; Themis Bioscience, Vienna, Austria, a subsidiary of Merck & Co, Rahway, NJ, USA.
  • Ramsauer K; Themis Bioscience, Vienna, Austria, a subsidiary of Merck & Co, Rahway, NJ, USA.
  • Baize S; Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Lyon, France; Centre International de Recherche en Infectiologie, Université de Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, Lyon, France.
Lancet ; 401(10384): 1267-1276, 2023 04 15.
Article en En | MEDLINE | ID: mdl-36934733
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Fiebre de Lassa / Sarampión Tipo de estudio: Clinical_trials Límite: Adult / Humans Idioma: En Revista: Lancet Año: 2023 Tipo del documento: Article
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Fiebre de Lassa / Sarampión Tipo de estudio: Clinical_trials Límite: Adult / Humans Idioma: En Revista: Lancet Año: 2023 Tipo del documento: Article